All In Biotech

Drug Trial Radar · NCT04486833

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Sep 3, 2021

Primary completion

Mar 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Genprex, Inc.Industry
Sponsor type
Industry
First posted
Jul 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

  • quaratusugene ozeplasmidBiological

    Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

  • osimertinibDrug

    Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.

  • Platinum-Based ChemotherapyDrug

    Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D) - Phase 1Time frame: First 21-day treatment cycle for each dose level cohort
  2. Overall Response Rate (ORR) - Phase 2aTime frame: Approximately 3 months
  3. Progression-free Survival (PFS) - Phase 2bTime frame: Approximately 11 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Carle Cancer Institute

    Urbana, Illinois · Recruiting

  • Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Maryland Oncology Hematology

    Rockville, Maryland · Terminated

  • The Valley Hospital - Luckow Pavilion

    Paramus, New Jersey · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • Millennium Oncology

    Houston, Texas · Terminated

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.